Oppenheimer on Intellia Therapeutics (NTLA): 'We view the resolution of the clinical trial holds for nex-z as relatively fast and favorable'
Tweet Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $27.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
